drugset / Trial / NCT06714864
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.
Timeline
- Start
- 2025-07-08
- Primary completion
- 2028-07
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Heparin | Other / unclassified | — | Other |
| Subject | taurolidine | Small molecule | — | Other |